QQQ   431.53 (+0.11%)
AAPL   169.16 (-2.04%)
MSFT   415.86 (+0.54%)
META   501.63 (+0.28%)
GOOGL   154.94 (+0.05%)
AMZN   183.64 (+0.01%)
TSLA   156.16 (-3.29%)
NVDA   875.80 (+1.84%)
AMD   163.29 (+1.85%)
NIO   3.85 (-1.03%)
BABA   69.79 (-1.18%)
T   15.98 (-1.60%)
F   12.13 (-0.82%)
MU   121.52 (+0.12%)
GE   155.59 (+1.23%)
CGC   6.85 (-1.86%)
DIS   113.79 (+0.74%)
AMC   2.80 (+13.36%)
PFE   25.75 (-0.62%)
PYPL   63.75 (+0.38%)
XOM   118.42 (-1.05%)
QQQ   431.53 (+0.11%)
AAPL   169.16 (-2.04%)
MSFT   415.86 (+0.54%)
META   501.63 (+0.28%)
GOOGL   154.94 (+0.05%)
AMZN   183.64 (+0.01%)
TSLA   156.16 (-3.29%)
NVDA   875.80 (+1.84%)
AMD   163.29 (+1.85%)
NIO   3.85 (-1.03%)
BABA   69.79 (-1.18%)
T   15.98 (-1.60%)
F   12.13 (-0.82%)
MU   121.52 (+0.12%)
GE   155.59 (+1.23%)
CGC   6.85 (-1.86%)
DIS   113.79 (+0.74%)
AMC   2.80 (+13.36%)
PFE   25.75 (-0.62%)
PYPL   63.75 (+0.38%)
XOM   118.42 (-1.05%)
QQQ   431.53 (+0.11%)
AAPL   169.16 (-2.04%)
MSFT   415.86 (+0.54%)
META   501.63 (+0.28%)
GOOGL   154.94 (+0.05%)
AMZN   183.64 (+0.01%)
TSLA   156.16 (-3.29%)
NVDA   875.80 (+1.84%)
AMD   163.29 (+1.85%)
NIO   3.85 (-1.03%)
BABA   69.79 (-1.18%)
T   15.98 (-1.60%)
F   12.13 (-0.82%)
MU   121.52 (+0.12%)
GE   155.59 (+1.23%)
CGC   6.85 (-1.86%)
DIS   113.79 (+0.74%)
AMC   2.80 (+13.36%)
PFE   25.75 (-0.62%)
PYPL   63.75 (+0.38%)
XOM   118.42 (-1.05%)
QQQ   431.53 (+0.11%)
AAPL   169.16 (-2.04%)
MSFT   415.86 (+0.54%)
META   501.63 (+0.28%)
GOOGL   154.94 (+0.05%)
AMZN   183.64 (+0.01%)
TSLA   156.16 (-3.29%)
NVDA   875.80 (+1.84%)
AMD   163.29 (+1.85%)
NIO   3.85 (-1.03%)
BABA   69.79 (-1.18%)
T   15.98 (-1.60%)
F   12.13 (-0.82%)
MU   121.52 (+0.12%)
GE   155.59 (+1.23%)
CGC   6.85 (-1.86%)
DIS   113.79 (+0.74%)
AMC   2.80 (+13.36%)
PFE   25.75 (-0.62%)
PYPL   63.75 (+0.38%)
XOM   118.42 (-1.05%)
Free Trial
NASDAQ:VVUS

VIVUS (VVUS) Stock Price, News & Analysis

→ Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad)
Free VVUS Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$0.26
▼
$0.47
52-Week Range
N/A
Volume
2.03 million shs
Average Volume
1.44 million shs
Market Capitalization
$7.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
VVUS stock logo

About VIVUS Stock (NASDAQ:VVUS)

VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.

VVUS Stock News Headlines

January 8, 2024 | markets.businessinsider.com
VIVUS Provides Update on Pipeline and Program Milestones
May 25, 2023 | it.tmcnet.com
Metaview announces Answers, the world's first conversational AI for the interview process
April 16, 2024 | Manward Press (Ad)
Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
October 2, 2022 | marketwatch.com
Why aren’t new drugs that can help you lose weight more widely used? - MarketWatch
October 2, 2022 | morningstar.com
'There's no way that patients are going to be able to afford that.' Why aren't new drugs that can help you lose weight more widely used? - Morningstar
September 23, 2022 | finance.yahoo.com
Erectile Dysfunction Drugs Market to Surpass Around USD 4079.9 Million by 2028, Says Brandessence Market Research - Yahoo Finance
September 16, 2022 | streetinsider.com
Form DEF 14A Catalent, Inc. For: Oct 27 - StreetInsider.com
September 9, 2022 | globenewswire.com
Obesity Management Market Expanding at an Impressive CAGR - GlobeNewswire
April 16, 2024 | Manward Press (Ad)
Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
August 26, 2022 | finance.yahoo.com
Global Human Reproductive Technology Products and Markets Analysis Report 2022: Data from 2020-2021, Estimates for 2022, and CAGR Projections through 2027 - Yahoo Finance
August 26, 2022 | prnewswire.com
Global Human Reproductive Technology Products and Markets Analysis Report 2022: Data from 2020-2021, Estimates for 2022, and CAGR Projections through 2027 - PR Newswire
August 17, 2022 | stockhouse.com
2022-08-15 | NDAQ:PTPI | Press Release | Petros Pharmaceuticals Inc. - Stockhouse
August 15, 2022 | streetinsider.com
Petros Pharmaceuticals Reports Record Revenue and Gross Profit During Second Quarter 2022 - StreetInsider.com
August 11, 2022 | finance.yahoo.com
Kaléo Announces Executive Appointments and New Government Business Unit - Yahoo Finance
August 5, 2022 | marketscreener.com
Icahn Enterprises L P : Reports Second Quarter 2022 Financial Results - Form 8-K - Marketscreener.com
August 2, 2022 | benzinga.com
Global Cystic Fibrosis Market Report 2022-2030: CFTR Modulators Segment to Dominate the Market - Benzinga
July 31, 2022 | businesswire.com
Global Cystic Fibrosis Market Report 2022: Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts 2020-2030 - ResearchAndMarkets.com - Business Wire
July 26, 2022 | globenewswire.com
Global Achondroplasia Market to Surpass US$ 1100.97 Million by 2030, Says Coherent Market Insights (CMI) - GlobeNewswire
July 14, 2022 | fortune.com
The best stock investing strategy for 2022: Don’t buy the dip, buy the dividend - Fortune
July 5, 2022 | finance.yahoo.com
BioXcel Therapeutics Appoints Michael P. Miller to Board of Directors - Yahoo Finance
July 5, 2022 | streetinsider.com
BioXcel Therapeutics Appoints Michael P. Miller to Board of Directors - StreetInsider.com
June 8, 2022 | benzinga.com
Overweight Treatment Market estimated to surge ahead at a CAGR of 7.9% by the end of 2032 - Persistence M - Benzinga
May 16, 2022 | stockhouse.com
2022-05-16 | NDAQ:PTPI | Press Release | Petros Pharmaceuticals Inc. - Stockhouse
May 6, 2022 | fool.com
Icahn Enterprises (IEP) Q1 2022 Earnings Call Transcript - The Motley Fool
May 3, 2022 | gurufocus.com
Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company's Novel Topical Investigational Treatment for Peyronie's Disease Which Impacts More Than 1 in 10 Men in the US - GuruFocus.com
May 3, 2022 | globenewswire.com
Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company's Novel Topical Investigational Treatment for Peyronie's Disease Which Impacts More Than 1 in 10 Men in the US - GlobeNewswire
April 27, 2022 | gurufocus.com
Petros Pharmaceuticals, Inc. Engages Massachusetts General Hospital in a Sponsored Research Agreement for Tissue-Specific Oxygenation Sensor Technology - GuruFocus.com
See More Headlines
Receive VVUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VIVUS and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/06/2020
Today
4/16/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:VVUS
CUSIP
92855110
CIK
881524
Web
www.vivus.com
Phone
(650) 934-5200
Fax
N/A
Employees
57
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($2.96)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-31,500,000.00
Net Margins
-39.28%
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-12.18%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.43
Quick Ratio
0.28

Sales & Book Value

Annual Sales
$69.76 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($6.50) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
17,867,000
Free Float
N/A
Market Cap
$7.33 million
Optionable
Optionable
Beta
-0.84
13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • John P. Amos
    Chief Executive Officer & Director
  • Mark K. Oki
    Chief Financial & Accounting Officer, Senior VP
  • Santosh T. Varghese
    Chief Medical Officer & Senior Vice President
  • Ted Broman
    Vice President-Chemistry, Manufacturing & Control
  • Tracy Guo
    Vice President-Finance

Key Competitors

View All Competitors

VVUS Stock Analysis - Frequently Asked Questions

How were VIVUS's earnings last quarter?

VIVUS, Inc. (NASDAQ:VVUS) posted its quarterly earnings data on Wednesday, May, 6th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, beating analysts' consensus estimates of ($0.80) by $0.31. The biopharmaceutical company earned $19.63 million during the quarter.

When did VIVUS's stock split?

VIVUS's stock reverse split on the morning of Tuesday, September 11th 2018. The 1-10 reverse split was announced on Monday, September 10th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 10th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of VIVUS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VIVUS investors own include Fulcrum Therapeutics (FULC), Sangamo Therapeutics (SGMO), Anavex Life Sciences (AVXL), Novavax (NVAX), General Electric (GE), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Amarin (AMRN), Geron (GERN) and Idera Pharmaceuticals (IDRA).

This page (NASDAQ:VVUS) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Can't believe it's happening again
Manward Press
He Is Giving Away Bitcoin
Crypto Swap Profits
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Options trading has suddenly become more reliable.
Eagle Publishing
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
The Greatest Bull Market in Crypto History…
Weiss Ratings